Pharmabiz

GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol

GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol: Chalfont St Giles,?UK Saturday, April 25, 2026, 12:00 Hrs [IST] ...
Business Wire

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

(CNW) Bracco Receives Health Canada Approval for VUEWAY(R) injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

MONTREAL, April 17, 2026 /CNW/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY (R) injection (gadopiclenol), a macrocyclic gadolinium-based ...
Pharmabiz

Japan MHLW approves Bayer’s low-dose MRI contrast agent, Ambelvist

Bayer announced the world’s first approval of the MRI contrast agent gadoquatrane by the Ministry of Health, Labour, and Welfare in Japan. The next-generation high relaxivity low-dose macrocyclic ...